Accelerate Diagnostics Inc EBITDA margin
What is the EBITDA margin of Accelerate Diagnostics Inc?
The EBITDA margin of Accelerate Diagnostics Inc is -609.36%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to Accelerate Diagnostics Inc
What does Accelerate Diagnostics Inc do?
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Companies with ebitda margin similar to Accelerate Diagnostics Inc
- KULR Technology has EBITDA margin of -615.27%
- Sorrento Therapeutics has EBITDA margin of -614.74%
- Cohen & Steers MLP Income and Opportunity Fund Inc has EBITDA margin of -614.53%
- Cue Biopharma Inc has EBITDA margin of -612.37%
- Neuropathix has EBITDA margin of -612.32%
- Suven Life Sciences has EBITDA margin of -609.59%
- Accelerate Diagnostics Inc has EBITDA margin of -609.36%
- ProStar has EBITDA margin of -608.76%
- ClearVue Technologies has EBITDA margin of -608.61%
- e Actiplay SA has EBITDA margin of -606.92%
- iBio Inc has EBITDA margin of -606.29%
- GlycoMimetics Inc has EBITDA margin of -604.90%
- Æterna Zentaris has EBITDA margin of -603.74%